U.S. Point-Of-Care Molecular Diagnostics Market Size & Outlook
- Clinical Diagnostics
- Cancer Diagnostics
- Point-of-Care Molecular Diagnostics Market Outlook
- Cancer Diagnostics
Global Market
Related Markets
Ask Prism AI anything about the point-of-care molecular diagnostics market
Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.
U.S. point-of-care molecular diagnostics market highlights
- The U.S. point-of-care molecular diagnostics market generated a revenue of USD 3,228.0 million in 2024 and is expected to reach USD 5,192.3 million by 2033.
- The U.S. market is expected to grow at a CAGR of 5.5% from 2025 to 2033.
- In terms of segment, infectious diseases was the largest revenue generating application in 2024.
- Oncology is the most lucrative application segment registering the fastest growth during the forecast period.
Point-of-care molecular diagnostics market data book summary
| Market revenue in 2024 | USD 3,228.0 million |
| Market revenue in 2033 | USD 5,192.3 million |
| Growth rate | 5.5% (CAGR from 2025 to 2033) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Oncology |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
| Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
Other key industry trends
- In terms of revenue, U.S. accounted for 39.3% of the global point-of-care molecular diagnostics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. point-of-care molecular diagnostics market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 410.6 million by 2033.
The U.S. leads the point-of-care molecular diagnostics market due to the local presence of leading players, such as Roche Diagnostics, Abbott, and Danaher. One of the reasons for their continued dominance is the presence of well-established R&D infrastructure and favorable reimbursement policies.
Furthermore, according to the American Cancer Society, in 2022, around 1,918,030 new cases of cancer and about 609,360 cancer deaths were anticipated in the U.S. alone. These factors are expected to contribute to the continued dominance of the U.S.
In addition, the regulatory & reimbursement landscape is continuously evolving to adapt to the fast-paced research progress in this sector. Moreover, the FDA is developing new regulatory strategies regarding NGS, which is anticipated to boost innovation in tests while ensuring that the data produced by these tests are accurate & reliable.
No credit card required*
Publish Date: Aug 05, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Point-Of-Care Molecular Diagnostics Market Scope
Point-Of-Care Molecular Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Abbott Laboratories | View profile | 114,000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | www.abbottinvestor.com |
| BioMerieux SA | View profile | 13,982 | Marcy l’Etoile, Lyon, France, 69280 | www.biomerieux.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Qiagen NV | View profile | 5,900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | www.qiagen.com |
| Nova Biomedical | View profile | 501-1000 | Waltham, Massachusetts, United States, North America | www.novabio.us |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Nipro Corp | View profile | 39,713 | 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 | www.nipro.co.jp |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
U.S. Point-of-Care Molecular Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Point-of-Care Molecular Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Infectious Diseases was the largest segment with a revenue share of 49.38% in 2024.
Horizon Databook has segmented the U.S. point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. leads the point-of-care molecular diagnostics market due to the local presence of leading players, such as Roche Diagnostics, Abbott, and Danaher. One of the reasons for their continued dominance is the presence of well-established R&D infrastructure and favorable reimbursement policies.
Furthermore, according to the American Cancer Society, in 2022, around 1,918,030 new cases of cancer and about 609,360 cancer deaths were anticipated in the U.S. alone. These factors are expected to contribute to the continued dominance of the U.S.
In addition, the regulatory & reimbursement landscape is continuously evolving to adapt to the fast-paced research progress in this sector. Moreover, the FDA is developing new regulatory strategies regarding NGS, which is anticipated to boost innovation in tests while ensuring that the data produced by these tests are accurate & reliable.
- U.S. Point-Of-Care Molecular Diagnostics Market Application Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Prenatal Testing
- Endocrinology
- Other Applications
- Hematology
- Infectious Diseases
- U.S. Point-Of-Care Molecular Diagnostics Market Technology Outlook (Revenue, USD Million , 2021-2033)
- PCR-based
- Genetic Sequencing based
- Hybridization based
- Microarray based
- U.S. Point-Of-Care Molecular Diagnostics Market Test Location Outlook (Revenue, USD Million , 2021-2033)
- OTC
- POC
- U.S. Point-Of-Care Molecular Diagnostics Market End-use Outlook (Revenue, USD Million , 2021-2033)
- Decentralised Labs
- Hospitals
- Home care
- Assisted Living Healthcare Facilities
- Others
Reasons to subscribe to Point-of-Care Molecular Diagnostics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Point-of-Care Molecular Diagnostics Market Outlook databook
- Our clientele includes a mix of Point-of-Care Molecular Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Point-of-Care Molecular Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Point-of-Care Molecular Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.S. Point-Of-Care Molecular Diagnostics Market, 2021-2033 (US$M)
US Application - Point-of-care Molecular Diagnostics Market Statistics, 2024 - 2033 (US$M)
